Memantine for the treatment of negative symptomatology and cognitive impairment in schizophrenia.

Trial Profile

Memantine for the treatment of negative symptomatology and cognitive impairment in schizophrenia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2013

At a glance

  • Drugs Memantine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Oct 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Feb 2012 Planned end date changed from 1 Jul 2010 to 1 Jul 2012 as reported by ClinicalTrials.gov.
    • 11 Aug 2009 Planned end date changed from 1 Jul 2009 to 1 Jul 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top